190 related articles for article (PubMed ID: 1967769)
1. Transdermal administration of oestrogen/progestagen hormone replacement therapy.
Whitehead MI; Fraser D; Schenkel L; Crook D; Stevenson JC
Lancet; 1990 Feb; 335(8685):310-2. PubMed ID: 1967769
[TBL] [Abstract][Full Text] [Related]
2. Does low-dose, transdermal, norethisterone acetate reliably cause endometrial transformation in postmenopausal oestrogen-users?
Fraser D; Whitehead M; Schenkel L; Pryse-Davies J
Maturitas; 1993 Jan; 16(1):23-30. PubMed ID: 8429801
[TBL] [Abstract][Full Text] [Related]
3. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study.
Wells M; Sturdee DW; Barlow DH; Ulrich LG; O'Brien K; Campbell MJ; Vessey MP; Bragg AJ
BMJ; 2002 Aug; 325(7358):239. PubMed ID: 12153918
[TBL] [Abstract][Full Text] [Related]
4. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
Johannisson E; Holinka CF; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
[TBL] [Abstract][Full Text] [Related]
5. Transdermal hormonal replacement therapy with transdermal progestin every second month.
Lindgren R; Risberg B; Hammar M; Berg G
Maturitas; 1995 Jun; 22(1):25-30. PubMed ID: 7666813
[TBL] [Abstract][Full Text] [Related]
6. Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women.
Brynhildsen J; Hammar M
Menopause; 2002; 9(2):137-44. PubMed ID: 11875333
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study.
Helle SI; Omsjø IH; Hughes SC; Botta L; Hüls G; Holly JM; Lønning PE
Clin Endocrinol (Oxf); 1996 Dec; 45(6):727-32. PubMed ID: 9039339
[TBL] [Abstract][Full Text] [Related]
8. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy.
Sturdee DW; Ulrich LG; Barlow DH; Wells M; Campbell MJ; Vessey MP; Nielsen B; Anderson MC; Bragg AJ
BJOG; 2000 Nov; 107(11):1392-400. PubMed ID: 11117768
[TBL] [Abstract][Full Text] [Related]
9. The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women.
Oosterbaan HP; van Buuren AH; Schram JH; van Kempen PJ; Ubachs JM; van Leusden HA; Beyer GP
Maturitas; 1995 Apr; 21(3):211-9. PubMed ID: 7616870
[TBL] [Abstract][Full Text] [Related]
10. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study.
Samsioe G; Boschitsch E; Concin H; De Geyter C; Ehrenborg A; Heikkinen J; Hobson R; Arguinzoniz M; Ibarra de Palacios P; Scheurer C; Schmidt G;
Climacteric; 2006 Oct; 9(5):368-79. PubMed ID: 17080587
[TBL] [Abstract][Full Text] [Related]
11. A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women.
Koninckx PR; Spielmann D
Gynecol Endocrinol; 2005 Aug; 21(2):82-9. PubMed ID: 16294460
[TBL] [Abstract][Full Text] [Related]
12. Endometrial effects of transdermal estradiol/norethisterone acetate.
Lindgren R; Risberg B; Hammar M; Berg G; Pryse-Davies J
Maturitas; 1992 Aug; 15(1):71-8. PubMed ID: 1528133
[TBL] [Abstract][Full Text] [Related]
13. A transdermal regimen for continuous combined hormone replacement therapy in the menopause.
Keller PJ; Hotz E; Imthurn B
Maturitas; 1992 Dec; 15(3):195-8. PubMed ID: 1465033
[TBL] [Abstract][Full Text] [Related]
14. Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women.
Perrone G; Falaschi P; Capri O; Pastore R; Galoppi P; D'Urso R; Martocchia A; Anelli G; Zichella L
Int J Fertil Menopausal Stud; 1994; 39(4):202-7. PubMed ID: 7951402
[TBL] [Abstract][Full Text] [Related]
15. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group.
Archer DF; Furst K; Tipping D; Dain MP; Vandepol C
Obstet Gynecol; 1999 Oct; 94(4):498-503. PubMed ID: 10511348
[TBL] [Abstract][Full Text] [Related]
16. Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women.
Cameron ST; Critchley HO; Glasier AF; Williams AR; Baird DT
Br J Obstet Gynaecol; 1997 Oct; 104(10):1184-90. PubMed ID: 9332998
[TBL] [Abstract][Full Text] [Related]
17. Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology.
Ross AH; Boyd ME; Colgan TJ; Ferenczy A; Fugere P; Lorrain J
Obstet Gynecol; 1993 Nov; 82(5):773-9. PubMed ID: 8414325
[TBL] [Abstract][Full Text] [Related]
18. The optimal dose of oral norethindrone acetate for addition to transdermal estradiol: a multicenter study.
Fraser DI; Parsons A; Whitehead MI; Wordsworth J; Stuart G; Pryse-Davies J
Fertil Steril; 1990 Mar; 53(3):460-8. PubMed ID: 2407564
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy by the transdermal administration of oestradiol and norethisterone.
Norman-Taylor JQ; Crawford FE; Jenkins AW; Grudzinskas JG
Maturitas; 1994 Mar; 18(3):221-8. PubMed ID: 8015505
[TBL] [Abstract][Full Text] [Related]
20. Comparison between 1 year oral and transdermal oestradiol and sequential norethisterone acetate on circulating concentrations of leptin in postmenopausal women.
Laivuori H; Koistinen HA; Karonen SL; Cacciatore B; Ylikorkala O
Hum Reprod; 2001 Aug; 16(8):1632-5. PubMed ID: 11473954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
